Impaired intake of neurotransmitters leads to accumulation of toxic dopamine and neurodegeneration in patients with Parkinson’s disease, according to a new Northwestern Medicine study. The study, “LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson’s disease,” appeared in the journal…
Excessive levels of calcium in the brain may trigger the formation of toxic protein clumps that typify Parkinson’s disease. This finding could be a new treatment target for researchers working to understand how and why people develop the neurodegenerative disease. The research, “C-terminal calcium binding of α-synuclein modulates synaptic vesicle…
Squalamine, a natural product known for its cancer- and infection-fighting qualities, has shown promise as a treatment for Parkinson’s disease, according to preliminary results of a new study. The research, “A Natural Product Inhibits The Initiation Of α-Synuclein Aggregation And Suppresses Its Toxicity,” was published in the journal…
Recent research has shed light on the pathology of Parkinson’s disease by explaining how alpha-synuclein, a protein closely related to the disease, functions in a normal human brain. Findings may contribute to the design of future novel and appropriate therapies for Parkinson’s disease. The study, “Structural Basis Of Synaptic Vesicle Assembly…
A recent publication in the journal Nature Genetics describes a new genetic cause of Parkinson’s disease. The newly identified gene, called TMEM230, is involved in storage and release of the neurotransmitter dopamine from neurons. The findings open up new avenues of research into mechanisms leading to the…
Get regular updates to your inbox.
Notifications
